← Back to Clinical Trials
Recruiting NCT05281757

NCT05281757 Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Complex

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05281757
Status Recruiting
Phase
Sponsor Aesculap AG
Condition Hyperkyphosis
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2022-02-18
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
posterior stabilization for the cervical spine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2022-02-18 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Multicenter, multinational Post-Market Clinical Follow-Up (PMCF) study on the safety and performance of Ennovate® Complex - A prospective, pure data collection of all Ennovate® scoliosis patients in selected centers (not interventional, multicentric)

Eligibility Criteria

Inclusion Criteria: * Informed consent in the documentation of clinical and radiological results of patients who are minimum 18 years old * Informed consent in the documentation of clinical and radiological results of patients AND legal representative (parent) for patients who are younger than 18 * Patient's indication according to IFU * Patient is not pregnant Exclusion Criteria: * Patient's clear unability or unwillingness to participate in follow-up examinations

Contact & Investigator

Central Contact

Sarah Mattes

✉ sarah.mattes@aesculap.de

📞 +497461950

Principal Investigator

Mohd Hisam, Prof. Dr.

PRINCIPAL INVESTIGATOR

Hospital Universiti Kebangsaan Malaysia (HUKM)

Frequently Asked Questions

Who can join the NCT05281757 clinical trial?

This trial is open to participants of all sexes, studying Hyperkyphosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05281757 currently recruiting?

Yes, NCT05281757 is actively recruiting participants. Contact the research team at sarah.mattes@aesculap.de for enrollment information.

Where is the NCT05281757 trial being conducted?

This trial is being conducted at Brno, Czechia, Kuala Lumpur, Malaysia.

Who is sponsoring the NCT05281757 clinical trial?

NCT05281757 is sponsored by Aesculap AG. The principal investigator is Mohd Hisam, Prof. Dr. at Hospital Universiti Kebangsaan Malaysia (HUKM). The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology